One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
Authors:
- Martin GauthierMGMartin Gauthier
- Christian KobaCKChristian Koba
Open Access
- 1 October 2024
- journal article
- Published by AME Publishing Company in AME Clinical Trials Review
- Vol. 2, 90